Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ramucirumab by Eli Lilly and Co for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Adenocarcinoma of The...
Crenigacestat by Eli Lilly and Co for Natural Killer Cell Lymphomas: Likelihood of Approval
Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase I for Natural Killer Cell Lymphomas....
Ramucirumab by Eli Lilly and Co for Esophageal Cancer: Likelihood of Approval
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Esophageal Cancer. According to...
Abemaciclib by Eli Lilly and Co for Ewing Sarcoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Ewing Sarcoma. According to...
Abemaciclib by Eli Lilly and Co for Dedifferentiated Liposarcoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Dedifferentiated Liposarcoma. According to...
Abemaciclib by Eli Lilly and Co for Central Nervous System (CNS) Tumor: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Central Nervous System (CNS)...
Abemaciclib by Eli Lilly and Co for Neuroblastoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Neuroblastoma. According to GlobalData,...
Ucenprubart by Eli Lilly and Co for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Ucenprubart is under clinical development by Eli Lilly and Co and currently in Phase II for Atopic Dermatitis (Atopic Eczema)....
CFTX-1554 by Eli Lilly and Co for Neuropathic Pain (Neuralgia): Likelihood of Approval
CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Neuropathic Pain (Neuralgia). According...
LY-3537021 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval
LY-3537021 is under clinical development by Eli Lilly and Co and currently in Phase I for Type 2 Diabetes. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-001?
PR-001 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Parkinson's Disease....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Peresolimab?
Peresolimab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Autoimmune Disorders....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's LY-3372689?
LY-3372689 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Alzheimer's Disease....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Imlunestrant tosylate?
Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Metastatic...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Muvalaplin?
Muvalaplin is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Atherosclerosis. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Solbinsiran Sodium?
Solbinsiran Sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase II program in...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Remternetug?
Remternetug is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase III program in Alzheimer's Disease....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Mevidalen Hydroxybenzoate?
Mevidalen Hydroxybenzoate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Lewy...
Alimta by Eli Lilly and Co for Chordoma: Likelihood of Approval
Alimta is under clinical development by Eli Lilly and Co and currently in Phase I for Chordoma. According to GlobalData,...
Eli Lilly and Co files patent for ret kinase inhibitors
Eli Lilly and Co. has filed a patent for RET kinase inhibitors, which are compounds used in the treatment of...